Self.co is Scaling Affordable Allergy Testing Across Europe

Self.co, a Lithuania-based company, helping you uncover the true cause of your symptoms and guide you toward the right path to better health, led by Tautvydas Gylys, Gintautas Gylys, and Juozapas Zabukas, has secured €2.56 million in funding, including €1.2 million led by Iron Wolf Capital, joined by Coinvest, NGL Ventures, and several angel investors, and a €1.36 million government grant from Innovation Agency Lithuania.

Nearly 40% of people worldwide suffer from allergies or food intolerances, yet testing remains costly and slow. Lithuanian health startup Self.co offers an accessible alternative, molecular tests priced between €69 and €99, providing fast, reliable results through its digital platform.

Co-founder and CEO Tautvydas Gylys said, “Millions experience allergy-like symptoms without knowing why. We’ve made advanced diagnostics simple and affordable, giving everyone clear, medically valid answers without the high cost or long wait.”

Founded in 2015 by Gintautas and Tautvydas Gylys, Self.co was created to make allergy diagnostics accessible and affordable. Built on Gintautas’s in-house molecular testing innovation, the company developed a microarray platform that detects over 300 allergens and food markers from a small blood sample.

Using AI-driven analysis, Self.co delivers precise, personalised reports with clear guidance on avoidance and treatment. By managing every step, from technology to testing, the company offers lab-grade accuracy at a fraction of the cost, standing apart from traditional and digital competitors alike.

Self.co plans to evolve into a comprehensive digital health ecosystem, aiming to become Europe’s leading platform for allergy diagnosis and management by 2030. Upcoming features include a smart questionnaire for better test selection, expanded testing for lactose and histamine intolerance, a dry-blood collection device, and partnerships with insurers.

Kasparas Jurgelionis, Managing Partner at Iron Wolf Capital, noted that Self.co is poised to redefine allergy care globally, addressing long-standing pain points for patients and clinicians while driving healthcare innovation at scale.